KINIKSA PHARMACEUTICALS INTE (KNSA) Stock Fundamental Analysis
NASDAQ:KNSA - Nasdaq - GB00BRXB0C07 - Common Stock - Currency: USD
We assign a fundamental rating of 6 out of 10 to KNSA. KNSA was compared to 551 industry peers in the Biotechnology industry. KNSA has an excellent financial health rating, but there are some minor concerns on its profitability. KNSA is not priced too expensively while it is growing strongly. Keep and eye on this one! These ratings would make KNSA suitable for growth investing!
1. Profitability
1.1 Basic Checks
KNSA had positive earnings in the past year.
KNSA had a positive operating cash flow in the past year.
In multiple years KNSA reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: KNSA reported negative operating cash flow in multiple years.
1.2 Ratios
The Return On Assets of KNSA (0.72%) is better than 90.20% of its industry peers.
KNSA has a better Return On Equity (0.97%) than 91.29% of its industry peers.
Looking at the Return On Invested Capital, with a value of 0.65%, KNSA belongs to the top of the industry, outperforming 91.47% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.72% | ||
| ROE | 0.97% | ||
| ROIC | 0.65% |
ROA(3y)11.71%
ROA(5y)-15.78%
ROE(3y)13.22%
ROE(5y)-19.49%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
KNSA has a better Profit Margin (0.90%) than 90.74% of its industry peers.
Looking at the Operating Margin, with a value of 0.85%, KNSA belongs to the top of the industry, outperforming 91.29% of the companies in the same industry.
The Gross Margin of KNSA (85.93%) is better than 89.11% of its industry peers.
In the last couple of years the Gross Margin of KNSA has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 0.85% | ||
| PM (TTM) | 0.9% | ||
| GM | 85.93% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.87%
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), KNSA is destroying value.
The number of shares outstanding for KNSA has been increased compared to 1 year ago.
KNSA has more shares outstanding than it did 5 years ago.
KNSA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
KNSA has an Altman-Z score of 9.19. This indicates that KNSA is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 9.19, KNSA belongs to the top of the industry, outperforming 85.30% of the companies in the same industry.
KNSA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 9.19 |
ROIC/WACC0.07
WACC9.16%
2.3 Liquidity
A Current Ratio of 3.57 indicates that KNSA has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 3.57, KNSA is in line with its industry, outperforming 41.92% of the companies in the same industry.
KNSA has a Quick Ratio of 3.16. This indicates that KNSA is financially healthy and has no problem in meeting its short term obligations.
KNSA has a worse Quick ratio (3.16) than 61.34% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.57 | ||
| Quick Ratio | 3.16 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 125.00% over the past year.
Looking at the last year, KNSA shows a very strong growth in Revenue. The Revenue has grown by 56.18%.
The Revenue has been growing by 122.27% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)125%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%483.33%
Revenue 1Y (TTM)56.18%
Revenue growth 3Y122.27%
Revenue growth 5YN/A
Sales Q2Q%51.65%
3.2 Future
KNSA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 45.55% yearly.
KNSA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 21.89% yearly.
EPS Next Y221.23%
EPS Next 2Y83.61%
EPS Next 3Y71.89%
EPS Next 5Y45.55%
Revenue Next Year34.22%
Revenue Next 2Y30.51%
Revenue Next 3Y25.67%
Revenue Next 5Y21.89%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
KNSA is valuated quite expensively with a Price/Earnings ratio of 803.75.
89.84% of the companies in the same industry are more expensive than KNSA, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of KNSA to the average of the S&P500 Index (26.48), we can say KNSA is valued expensively.
A Price/Forward Earnings ratio of 38.44 indicates a quite expensive valuation of KNSA.
Compared to the rest of the industry, the Price/Forward Earnings ratio of KNSA indicates a rather cheap valuation: KNSA is cheaper than 89.84% of the companies listed in the same industry.
KNSA's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 34.04.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 803.75 | ||
| Fwd PE | 38.44 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, KNSA is valued cheaply inside the industry as 90.20% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, KNSA is valued cheaply inside the industry as 92.92% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 35.83 | ||
| EV/EBITDA | 339.68 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The decent profitability rating of KNSA may justify a higher PE ratio.
A more expensive valuation may be justified as KNSA's earnings are expected to grow with 71.89% in the coming years.
PEG (NY)3.63
PEG (5Y)N/A
EPS Next 2Y83.61%
EPS Next 3Y71.89%
5. Dividend
5.1 Amount
KNSA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
32.15
-0.96 (-2.9%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners96.04%
Inst Owner Change-6.23%
Ins Owners3.91%
Ins Owner Change-0.12%
Market Cap2.38B
Analysts86.67
Price Target45.7 (42.15%)
Short Float %6.22%
Short Ratio3.21
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)90.27%
Min EPS beat(2)23.78%
Max EPS beat(2)156.77%
EPS beat(4)2
Avg EPS beat(4)-1563.32%
Min EPS beat(4)-5782.35%
Max EPS beat(4)156.77%
EPS beat(8)4
Avg EPS beat(8)-744.22%
EPS beat(12)8
Avg EPS beat(12)-441.01%
EPS beat(16)11
Avg EPS beat(16)-327.1%
Revenue beat(2)2
Avg Revenue beat(2)4.26%
Min Revenue beat(2)3.54%
Max Revenue beat(2)4.99%
Revenue beat(4)2
Avg Revenue beat(4)1.14%
Min Revenue beat(4)-2.63%
Max Revenue beat(4)4.99%
Revenue beat(8)5
Avg Revenue beat(8)3.71%
Revenue beat(12)9
Avg Revenue beat(12)8.66%
Revenue beat(16)11
Avg Revenue beat(16)8.77%
PT rev (1m)6.63%
PT rev (3m)8.51%
EPS NQ rev (1m)28.29%
EPS NQ rev (3m)30.12%
EPS NY rev (1m)0%
EPS NY rev (3m)41.05%
Revenue NQ rev (1m)0.83%
Revenue NQ rev (3m)2.26%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 803.75 | ||
| Fwd PE | 38.44 | ||
| P/S | 4.5 | ||
| P/FCF | 35.83 | ||
| P/OCF | 35.59 | ||
| P/B | 4.81 | ||
| P/tB | 4.97 | ||
| EV/EBITDA | 339.68 |
EPS(TTM)0.04
EY0.12%
EPS(NY)0.84
Fwd EY2.6%
FCF(TTM)0.9
FCFY2.79%
OCF(TTM)0.9
OCFY2.81%
SpS7.14
BVpS6.68
TBVpS6.47
PEG (NY)3.63
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.72% | ||
| ROE | 0.97% | ||
| ROCE | 0.82% | ||
| ROIC | 0.65% | ||
| ROICexc | 1.5% | ||
| ROICexgc | 1.61% | ||
| OM | 0.85% | ||
| PM (TTM) | 0.9% | ||
| GM | 85.93% | ||
| FCFM | 12.56% |
ROA(3y)11.71%
ROA(5y)-15.78%
ROE(3y)13.22%
ROE(5y)-19.49%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.87%
GM growth 5YN/A
F-Score6
Asset Turnover0.8
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 30.43% | ||
| Cap/Sales | 0.09% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 1120.09% | ||
| Profit Quality | 1388.12% | ||
| Current Ratio | 3.57 | ||
| Quick Ratio | 3.16 | ||
| Altman-Z | 9.19 |
F-Score6
WACC9.16%
ROIC/WACC0.07
Cap/Depr(3y)8.83%
Cap/Depr(5y)180.67%
Cap/Sales(3y)0.05%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)125%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%483.33%
EPS Next Y221.23%
EPS Next 2Y83.61%
EPS Next 3Y71.89%
EPS Next 5Y45.55%
Revenue 1Y (TTM)56.18%
Revenue growth 3Y122.27%
Revenue growth 5YN/A
Sales Q2Q%51.65%
Revenue Next Year34.22%
Revenue Next 2Y30.51%
Revenue Next 3Y25.67%
Revenue Next 5Y21.89%
EBIT growth 1Y116.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year349.96%
EBIT Next 3Y109.32%
EBIT Next 5YN/A
FCF growth 1Y56.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y57.64%
OCF growth 3YN/A
OCF growth 5YN/A